<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4235">
  <stage>Registered</stage>
  <submitdate>30/12/2013</submitdate>
  <approvaldate>30/12/2013</approvaldate>
  <nctid>NCT02026401</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>13-0103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary Biliary Cirrhosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - NGM282
Other interventions - Placebo

Experimental: NGM282 Dose 1 - NGM282 Dose 1

Experimental: NGM282 Dose 2 - NGM282 Dose 2

Placebo Comparator: Placebo - Placebo


Other interventions: NGM282


Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change in plasma ALP from Baseline to Day 28</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in bilirubin from Baseline to Day 28</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males or females, between 18 and 75 years of age, inclusive

          -  PBC diagnosis consistent with AASLD and EASL guidelines

          -  Stable dose of UDCA</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Chronic liver disease of a non-PBC etiology

          -  Evidence of clinically significant hepatic decompensation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>45</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>NGM Clinical Study Site 602 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 606 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 609 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 611 - Sydney</hospital>
    <hospital>NGM Clinical Study Site 614 - Brisbane</hospital>
    <hospital>NGM Clinical Study Site 607 - Adelaide</hospital>
    <hospital>NGM Clinical Study Site 608 - Adelaide</hospital>
    <hospital>NGM Clinical Study Site 601 - Melbourne</hospital>
    <hospital>NGM Clinical Study Site 604 - Melbourne</hospital>
    <hospital>NGM Clinical Study Site 613 - Melbourne</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>NGM Biopharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>NGM Biopharmaceuticals Australia Pty Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in
      patients with Primary Biliary Cirrhosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02026401</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen J Rossi, PharmD</name>
      <address>NGM Biopharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>